Osteopontin is a therapeutic target that drives breast cancer recurrence.

Recurrent breast cancers often develop resistance to standard-of-care therapies. Identifying targetable factors contributing to cancer recurrence remains the rate-limiting step in improving long-term outcomes. In this study, we identify tumor cell-derived osteopontin as an autocrine and paracrine driver of tumor recurrence.

Clinical Effect of Descent in Infants with Bronchiolitis Diagnosed at Altitude: A Prospective Multicenter Study.

Poirier, Anne, Amélie Basso, Sarah Bonnet-Ducrot, Ellen Katranji, Sophia Cherif-Alami, Sophie Chateigner-Coelsch, Manon Navarre, Cécile Ricard, and Corentin Tanné. Clinical Effect of Descent in Infants with Bronchiolitis Diagnosed at Altitude: A Prospective Multicenter Study. 00:00-00, 2024.

Contributions and future potential of animal models for geroscience research on sensory systems.

Sensory systems mediate our social interactions, food intake, livelihoods, and other essential daily functions. Age-related decline and disease in sensory systems pose a significant challenge to healthy aging. Research on sensory decline in humans is informative but can often be difficult, subject to sampling bias, and influenced by environmental variation.

An atypical mesenteric tumor: The intestinal mesenteric lipophagic granuloma.

The intestinal mesenteric lipophagic granuloma is a rare and benign mesenteric tumor originating from the differentiation of mesenteric nodes that evolve toward a characteristic volume increase that is responsible for a compressive effect on the adjacent structures.

RG7774 (Vicasinabin), an orally bioavailable cannabinoid receptor 2 (CB2R) agonist, decreases retinal vascular permeability, leukocyte adhesion, and ocular inflammation in animal models.

Introduction: Preclinical studies suggest that cannabinoid receptor type 2 (CB2R) activation has a therapeutic effect in animal models on chronic inflammation and vascular permeability, which are key pathological features of diabetic retinopathy (DR). A novel CB2R agonist, triazolopyrimidine RG7774, was generated through lead optimization of a high-throughput screening hit. The aim of this study was to characterize the pharmacology, absorption, distribution, metabolism, elimination, and toxicity (ADMET) profile of RG7774, and to explore its potential for managing the key pathological features associated with retinal disease in rodents.